Human Bioequivalence Study of Amphotericin B Liposome for Injection
Status:
RECRUITING
Trial end date:
2025-10-07
Target enrollment:
Participant gender:
Summary
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
Phase:
NA
Details
Lead Sponsor:
Sichuan Huiyu Pharmaceutical Co., Ltd
Collaborator:
Changsha King-eagle Med Technology Co., Ltd.
Treatments:
Amphotericin B Injections Long-Term Synaptic Depression